This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $65.00. The company’s shares closed yesterday ...

Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day moving average price is $20.82.

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s forecast for CRB-913 peak sales has been lowered to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

City spokeswoman Melinda Stotts confirmed Landon Cole Corbus, 28, of Quapaw, resigned February 28. Corbus is charged in Lawrence County 39th Judicial Circuit Court with theft and third-degree ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...